Enerzair Breezhaler · DIN 02501244 · 150 mcg & 50 mcg & 160 mcg · Inh Pd-capsule
Limited Use, Reason for Use code 627 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 627 required
Write on scriptReason for Use code 627 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 627
Reason for Use code 627
For the treatment of asthma in adult patients inadequately controlled with a maintenance combination of a long-acting beta-2 agonist (LABA) and a medium or high dose of an inhaled corticosteroid (ICS), who experienced one or more asthma exacerbations in the previous 12 months.
Coverage limit:
LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Enerzair Breezhaler · DIN 02501244
Manufacturer: Novartis Pharma Canada Inc.; listing date 2022-02-28
Health Canada: Marketed since 2020-11-05 · brand ENERZAIR BREEZHALER · ATC R03AL12 INDACATEROL, GLYCOPYRRONIUM BROMIDE AND MOMETASONE, R03AL12 INDACATEROL, GLYCOPYRRONIUM BROMIDE AND MOMETASONE · form Capsule · route Inhalation · ingredients MOMETASONE FUROATE 160 MCG, GLYCOPYRRONIUM (GLYCOPYRRONIUM BROMIDE) 50 MCG, INDACATEROL (INDACATEROL ACETATE) 150 MCG · company Novartis pharmaceuticals canada inc · schedule Prescription
Enerzair Breezhaler: Formulary list price $3.43 per unit (the source does not state the unit; exact figure $3.4277). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02501244)
Source record
DIN 02501244: Enerzair Breezhaler
Raw flags: sec12=Y, sec3=Y
Item: 680400122; group id 713; item number 1763; lccId 00355; manufacturer id NOV
Source form: Inh Pd-Cap; strength: 150mcg & 50mcg & 160mcg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $3.4277; ministry $3.4277
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02501244
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99087
Shortage status: resolved shortage (ended May 21, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02501244
Shortage record checked October 6, 2026